Adalimumab is effective in patients with inflammatory bowel disease in clinical remission on infliximab

被引：0
|
作者：
Khan, M. [1 ]
Heetun, Z. [1 ]
Moloney, J. [1 ]
Courtney, G. [1 ]
Aftab, A. R. [1 ]
机构：
[1] St Lukes Hosp, Kilkenny, Kilkenny, Ireland
来源：
IRISH JOURNAL OF MEDICAL SCIENCE | 2015年 / 184卷
关键词：
THERAPY; TRIAL;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5 (14S114)
引用
收藏
页码：S73 / S74
页数：2
相关论文
共 50 条
  • [1] Adalimumab or Infliximab for the Treatment of Inflammatory Bowel Disease Patients: Which Is More Effective?
    Carrillo-Ramos, Maria Jesus
    Duarte-Chang, Calixto
    Maldonado-Perez, Belen
    Beltran-Castano, Rocio
    Castro-Laria, Luisa
    Argueelles-Arias, Federico
    Benitez-Roldan, Antonio
    Caunedo-Alvarez, Angel
    Pellicer-Bautista, Francisco
    Herrerias, Juan M.
    GASTROENTEROLOGY, 2014, 146 (05) : S196 - S196
  • [2] Serum levels of infliximab and adalimumab are associated with deep remission in inflammatory bowel disease
    Pascual-Marmaneu, Oscar
    Belles-Medall, Maria D.
    Ferrando-Piqueres, Raul
    Almela-Notari, Pedro
    Mendoza-Aguilera, Maria
    Alvarez-Martin, Tamara
    FARMACIA HOSPITALARIA, 2021, 45 (05) : 225 - 233
  • [3] Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
    Kamal, Mahmoud E.
    Werida, Rehab H.
    Radwan, Mahasen A.
    Askar, Safaa R.
    Omran, Gamal A.
    El-Mohamdy, Marwa A.
    Hagag, Radwa S.
    INFLAMMOPHARMACOLOGY, 2024, 32 (05) : 3259 - 3269
  • [4] Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission
    Guerrero Puente, Lourdes
    Iglesias Flores, Eva
    Manuel Benitez, Jose
    Medina Medina, Rosario
    Salgueiro Rodriguez, Isabel
    Aguilar Melero, Patricia
    Cardenas Aranzana, Manuel Jesus
    Gonzalez Fernandez, Rafael
    Manzanares Martin, Barbara
    Garcia-Sanchez, Valle
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2017, 40 (09): : 595 - 604
  • [5] Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease
    Shannon Chang
    Stephen Hanauer
    Current Treatment Options in Gastroenterology, 2017, 15 (1) : 53 - 70
  • [6] Drug survival of infliximab and adalimumab in inflammatory bowel disease
    Erfan Asadipour
    Mona Kargar
    International Journal of Clinical Pharmacy, 2020, 42 : 1521 - 1523
  • [7] Drug survival of infliximab and adalimumab in inflammatory bowel disease
    Asadipour, Erfan
    Kargar, Mona
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (06) : 1521 - 1523
  • [8] Long Term Prognosis After Discontinuation of Infliximab in Patients With Inflammatory Bowel Disease in Clinical Remission
    Steenholdt, Casper
    Molazahi, Akbar
    Ainsworth, Mark A.
    Brynskov, Jorn
    Thomsen, Ole
    Seidelin, Jakob B.
    GASTROENTEROLOGY, 2012, 142 (05) : S204 - S204
  • [9] Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients
    Swaminath, A.
    Ullman, T.
    Rosen, M.
    Mayer, L.
    Lichtiger, S.
    Abreu, M. T.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (03) : 273 - 278
  • [10] Therapeutic drug monitoring in Paediatric inflammatory bowel disease on maintenance infliximab and adalimumab treatment improves clinical remission with a proactive approach
    Chadokufa, S.
    Sider, S.
    Huggett, B.
    Sawney, T.
    Shah, N.
    Baycheva, M.
    Perez, A. Zambrano
    Acton, N.
    Kiparissi, F.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S381 - S382
12345